Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that the U.S. Food and Drug Administration (FDA) has approved XOCOVA®...

Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo® (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine (AVD) for the treatment of adult and...

Foundation Medicine, Inc., a global, patient-focused precision medicine company, announced that it has received approvals from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx and...

BrainStorm Cell Therapeutics Inc. a leading developer of autologous stem cell therapies for neurodegenerative diseases, announced that Peter J. Pitts has been appointed to the Company's Board of...

Nestlé Health Science, a global leader in the science of nutrition, and IdB Holding S.p.A. (IdB), a global leader in the production of high potent active pharmaceutical ingredients for the...

Ori Biotech, a leader in cell and gene therapy (CGT) manufacturing technology, and ImmuXell Biotech, a Shanghai-based clinical-stage cell therapy company, announced their strategic partnership which...

SK bioscience announced that it has signed an agreement with Colombia's state-owned pharmaceutical company VECOL for vaccine technology transfer and local manufacturing cooperation as part of Colombia's...

LIB Therapeutics Inc. (LIB), a privately-held, biopharmaceutical company with a recently approved novel, monthly, small-dose, third-generation PCSK9 inhibitor, LEROCHOL® (lerodalcibep-liga),...

H. Lundbeck A/S (Lundbeck) announced that the Ministry of Food and Drug Safety (MFDS) of South Korea has granted marketing authorization for eptinezumab for use in adults with...

Hologic, Inc. and its subsidiary, Biotheranostics, Inc., announced new data demonstrating how the Breast Cancer Index® (BCI™) Test results influence extended endocrine therapy decisions for patients with...

Aspera Biomedicines Inc., a biotechnology company developing first-in-class therapies targeting cancer stem cells, announced that its second ADAR1p150 protein crystallization experiment has...

Galvanize Therapeutics, Inc., a commercial-stage medical technology company pioneering pulsed electric field (PEF) therapies for oncology and chronic lung disease, today announced that it received...